Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of CYP2C19 polymorphisms in the Lebanese population

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Clopidogrel is one of the most commonly prescribed drugs, as its combination with low-dose aspirin is the recommended oral anti-platelet therapy, to prevent ischaemic events following coronary syndromes or stent placement. Numerous recent studies have shown that polymorphisms in the gene encoding the cytochrome P450 (CYP450) 2C19 enzyme (CYP2C19) contribute to variability in response to clopidogrel; patients with certain common genetic variants of CYP2C19 (*2, *3) have a reduced metabolism of clopidogrel and have a higher rate of cardiovascular events or stent thrombosis compared to patients with the CYP2C19 (*1) allele. CYP2C19*2 is most common in Caucasians, Africans and Asians while CYP2C19*3 has been found mostly in Asians. Since the prevalence of these variants in the Lebanese population has not yet been reported, our aim was to determine the genotypes of CYP2C19 in our population. CYP2C19 (*1/*2/*3) variants were assessed by Polymerase Chain Reaction-Restriction Length Polymorphism (PCR–RFLP) assays in a representative sample of 161 unrelated healthy Lebanese volunteers. The allele frequencies of CYP2C19 *2 and *3 were 0.13 and 0.03. Carriers of the CYP2C19 *2 or *3 represented 24.2% of the subjects. Our data show no significant difference in the frequency of CYP2C19 allelic variants when compared to Caucasian populations and demonstrate that the application of the recent FDA recommendations would also be beneficial in Lebanon, allowing physicians to identify patients at high risk for atherothrombotic events, and eventually advising them to consider other antiplatelet medications or alternative dosing strategies in poor metabolizers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Patrono C, Bachmann F, Guetta V et al (2004) Expert consensus document on the use of antiplatelet agents. Eur Heat J 25:166–181

    Article  Google Scholar 

  2. Plavix (clopidogrel bisulfate) 75 mg tablets (2009) Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed June 19 2009

  3. Antman EM, Hand M, Armstrong PW et al (2008) Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210–247

    Article  PubMed  Google Scholar 

  4. Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7):e148–e304

    Article  PubMed  Google Scholar 

  5. Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621

    Article  PubMed  CAS  Google Scholar 

  6. Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189

    Article  PubMed  CAS  Google Scholar 

  7. Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502

    Article  PubMed  CAS  Google Scholar 

  8. Steinhubl SR, Berger PB, Mann JT III et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized trial. JAMA 288:2411–2420

    Article  PubMed  CAS  Google Scholar 

  9. Angiolillo DJ, Alfonso F (2007) Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 98:707–709

    PubMed  CAS  Google Scholar 

  10. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50:1822–1834

    Article  PubMed  CAS  Google Scholar 

  11. Wang TH, Bhatt DL, Topol EJ (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27:647–654

    Article  PubMed  Google Scholar 

  12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2004) PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 15:89–93

    Article  PubMed  Google Scholar 

  13. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2006) Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26:1895–1900

    Article  PubMed  CAS  Google Scholar 

  14. Brandt JT, Close SL, Iturria SJ et al (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–2436

    Article  PubMed  CAS  Google Scholar 

  15. Fontana P, Dupont A, Gandrille S et al (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989–995

    Article  PubMed  CAS  Google Scholar 

  16. Giusti B, Gori AM, Marcucci R et al (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 17:1057–1064

    Article  PubMed  CAS  Google Scholar 

  17. Hulot JS, Bura A, Villard E et al (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244–2247

    Article  PubMed  CAS  Google Scholar 

  18. Taubert D, von Beckerath N, Grimberg G et al (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486–501

    Article  PubMed  CAS  Google Scholar 

  19. Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drugeluting or bare-metal stents. J Am Coll Cardiol 51:1925–1934

    Article  PubMed  CAS  Google Scholar 

  20. Clarke TA, Waskell LA (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31:53–59

    Article  PubMed  CAS  Google Scholar 

  21. Robarge J, Fletcher R, Nguyen A, Thorn C (2006) Important Haplotype Information for CYP2C19. Pharmacogenomics Knowledge Base. http://www.pharmgkb.org/search/annotatedGene/cyp2c19/haplotype.jsp. Accessed 30 Sept 2006

  22. Smith SM, Judge HM, Peters G et al (2006) Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 17:250–258

    Article  PubMed  CAS  Google Scholar 

  23. Tabassome S, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:1–13

    Article  Google Scholar 

  24. Mega J, Close S, Wiviott S et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362

    Article  PubMed  CAS  Google Scholar 

  25. Fontana P, Senouf D, Mach F (2008) Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 121:463–468

    Article  PubMed  CAS  Google Scholar 

  26. Sameer AEI, Amany GM, Abdela AA, Fadel SA (2009) CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in gaza strip. Can J Clin Pharmacol 16(1):156–162

    Google Scholar 

  27. Zand N, Tajik N, Hoormand M, Moghaddam A, Milanian I (2005) Allele frequency of CYP2C19 gene polymorphisms in a healthy Iranian population. Int J Pharm Technol 4:124–128

    CAS  Google Scholar 

  28. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug (2010) Safety Announcement http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed 25 March 2010

  29. Flockhart DA (2007) Drug interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. http://medicine.iupui.edu/clinpharm/ddis/table.asp. Accessed 12 Jan 2009

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory, Saint George Hospital University Medical Center, Achrafieh Beirut 1100, 2807, Beirut, Lebanon

    Isabelle Djaffar Jureidini, Sose Keleshian, Rania Naoufal, Laila Zahed & Noha Hakime

  2. Onco-Hematology, Saint George Hospital University Medical Center, Beirut, Lebanon

    Nabil Chamseddine

Authors
  1. Isabelle Djaffar Jureidini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nabil Chamseddine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sose Keleshian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rania Naoufal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laila Zahed
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noha Hakime
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabelle Djaffar Jureidini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Djaffar Jureidini, I., Chamseddine, N., Keleshian, S. et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 38, 5449–5452 (2011). https://doi.org/10.1007/s11033-011-0700-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-011-0700-y

Keywords

Search

Navigation